Factors associated with psychiatric morbidity and hazardous alcohol use in Australian doctors

2010 ◽  
Vol 193 (4) ◽  
pp. 248-248
Author(s):  
Louise M Nash ◽  
Michele G Daly ◽  
Patrick J Kelly ◽  
Elizabeth H Van Ekert ◽  
Garry Walter ◽  
...  
2010 ◽  
Vol 193 (3) ◽  
pp. 161-166 ◽  
Author(s):  
Louise M Nash ◽  
Michele G Daly ◽  
Patrick J Kelly ◽  
Elizabeth H Van Ekert ◽  
Garry Walter ◽  
...  

2011 ◽  
Vol 194 (2) ◽  
pp. 104-104
Author(s):  
Louise M Nash ◽  
Michele G Daly ◽  
Patrick J Kelly ◽  
Elizabeth H Van Ekert ◽  
Garry Walter ◽  
...  

2021 ◽  
pp. 095646242110144
Author(s):  
Mayuko Takamiya ◽  
Kudawashe Takarinda ◽  
Shrish Balachandra ◽  
Musuka Godfrey ◽  
Elizabeth Radin ◽  
...  

We assessed the prevalence of isoniazid preventive therapy (IPT) uptake and explored factors associated with IPT non-uptake among people living with HIV (PLHIV) using nationally representative data from the Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) 2015–2016. This was a cross-sectional study of 3418 PLHIV ZIMPHIA participants eligible for IPT, aged ≥15 years and in HIV care. Logistic regression modeling was performed to assess factors associated with self-reported IPT uptake. All analyses accounted for multistage survey design. IPT uptake among PLHIV was 12.7% (95% confidence interval (CI): 11.4–14.1). After adjusting for sex, age, rural/urban residence, TB screening at the last clinic visit, and hazardous alcohol use, rural residence was the strongest factor associated with IPT non-uptake (adjusted OR (aOR): 2.39, 95% CI: 1.82–3.12). Isoniazid preventive therapy non-uptake having significant associations with no TB screening at the last HIV care (aOR: 2.07, 95% CI: 1.54–2.78) and with hazardous alcohol use only in urban areas (aOR: 10.74, 95% CI: 3.60–32.0) might suggest suboptimal IPT eligibility screening regardless of residence, but more so in rural areas. Self-reported IPT use among PLHIV in Zimbabwe was low, 2 years after beginning national scale-up. This shows the importance of good TB screening procedures for successful IPT implementation.


2017 ◽  
Vol 21 (7) ◽  
pp. 1914-1925 ◽  
Author(s):  
Heidi M. Crane ◽  
Mary E. McCaul ◽  
Geetanjali Chander ◽  
Heidi Hutton ◽  
Robin M. Nance ◽  
...  

Author(s):  
Lisa R. Miller-Matero ◽  
Julia Orlovskaia ◽  
Leah M. Hecht ◽  
Jordan M. Braciszeweski ◽  
Kellie M. Martens ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Janja Jazbar ◽  
Igor Locatelli ◽  
Mitja Kos

Abstract Background Understanding potentially modifiable factors that influence the risk of frailty is a key concern for the management of this urgent contemporary public health challenge. This study evaluates the association between the use of various medications or alcohol and the incidence of frailty among older adults. Methods This study was a retrospective cohort study on older adults (≥ 65 years) using data from the longitudinal Survey of Health, Ageing and Retirement in Europe (SHARE survey, 28 countries). Medication use was measured as taking several different groups of medications. Alcohol use was assessed with SHARE questions corresponding to AUDIT-C. The outcome measure was the incidence of frailty after two years, defined by frailty index (FI) and frailty phenotype (FP). A multiple logistic regression model was used to evaluate the association with adjustment for several potential confounding factors. Results Of the 14,665 FI-population participants, 1800 (12.3%) developed frailty within two years. Of the 8133 FP-population participants, 2798 (34.4%) developed pre-frailty and 247 (3.0%) developed frailty within two years of baseline. After adjustment for potential confounding variables, non-hazardous alcohol use (adjusted OR; 95% CI for the FI-population: 0.68; 0.60–0.77) and hazardous alcohol use (0.80; 0.68–0.93) are associated with lower incidence of frailty compared to no alcohol use. The odds of frailty are increased when taking medications; the largest effect size was observed in older adults taking medication for chronic bronchitis (adjusted OR; 95% CI for the FI-population: 2.45; 1.87–3.22), joint pain and other pain medication (2.26; 2.00–2.54), medication for coronary and other heart disease (1.72; 1.52–1.96), medication for diabetes (1.69; 1.46–1.96), and medication for anxiety, depression and sleep problems (1.56; 1.33–1.84). Additionally, the risk of frailty was increased with stroke, Parkinson’s disease and dementia. Conclusions Taking certain groups of medication was associated with increased incidence of frailty and pre-frailty, which might be due to either medication use or the underlying disease. Alcohol use was associated with a lower risk of pre-frailty and frailty compared to no alcohol use, which might be due to reverse causality or residual confounding. There was no significant interaction effect between medication groups and alcohol use on frailty incidence.


Sign in / Sign up

Export Citation Format

Share Document